GlycoEra's Breakthrough: Secures $130 Million for Pioneering Protein Degraders
Deal News | May 27, 2025 | Agent Capital LLC
GlycoEra AG, a biotechnology firm focused on developing cutting-edge extracellular protein degraders for autoimmune disease treatments, has successfully raised $130 million in an oversubscribed Series B funding round. The financing was spearheaded by Novo Holdings, with substantial contributions from a blend of new and existing investors, including Catalio Capital Management, LifeArc Ventures, Sofinnova Partners, and more. This significant capital injection will be allocated to advance GlycoEra's lead program, an innovative IgG4-targeted degrader, through clinical trials and to further broaden its pipeline of precision immunology treatments. GlycoEra's proprietary platform offers best-in-class protein degraders that promise high specificity and efficacy, highlighting both modularity and scalability. The company aims to commence first-in-human clinical trials for its lead candidate, GE8820, later in the year, targeting diseases such as myasthenia gravis and autoimmune encephalitis. GlycoEra's board has also expanded with new members from Catalio Capital Management and LifeArc Ventures.
Sectors
- Biotechnology
- Pharmaceuticals
- Private Equity and Venture Capital
Geography
- Switzerland – GlycoEra AG is headquartered in Wdenswil, Switzerland, indicating key geographical relevance.
- United States – Agent Capital and the reference to Newton, MA suggest an operational link to the U.S., relevant for investment activities.
Industry
- Biotechnology – GlycoEra AG operates within the biotechnology sector, focusing on developing protein degraders for autoimmune diseases.
- Pharmaceuticals – The focus on creating treatments for autoimmune diseases places GlycoEra AG within the pharmaceuticals sector.
- Private Equity and Venture Capital – Involvement of multiple investors including PE and VC firms such as Novo Holdings and Sofinnova Partners in the financing round.
Financials
- $130 million – The total amount raised in the Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| GlycoEra AG | Target Company | Company | Biotechnology company developing extracellular protein degraders for autoimmune diseases. |
| Novo Holdings | Lead Investor | Company | Investment company leading the $130 million Series B funding round for GlycoEra AG. |
| Catalio Capital Management | Investor | Company | Participated in the funding round for GlycoEra AG. |
| LifeArc Ventures | Investor | Company | Contributed to the funding round for GlycoEra AG. |
| Sofinnova Partners | Existing Investor | Company | Long-time investor in GlycoEra AG, participated in the Series B round. |
| Agent Capital | Investor | Company | Joined the funding syndicate for GlycoEra AG's Series B round. |
| MP Healthcare Venture Management | Investor | Company | A subsidiary of Mitsubishi Tanabe Pharma, participant in the funding round. |
| Max Klement | Partner at Novo Holdings | Person | Announced support for GlycoEra AG's innovative programs. |
| Ganesh Kaundinya, Ph.D. | President and CEO of GlycoEra AG | Person | Leading GlycoEra and its strategic advancement in protein degraders. |